Stereotaxis, Inc.
HealthcareAMEX:STXS · New York Stock Exchange American
+$0.02 today
Vol 0.19M · Avg 0.39M
Balance Sheet
Inspect the capital base behind the business
Review assets, liabilities, equity, cash, and debt to judge whether the company has the financial position to support future returns.
Balance Sheet
Assets, liabilities & equity
| Cash & Equivalents | $14.6M |
| Receivables | $9.6M |
| Inventory | $10.5M |
| Other Current | $1.1M |
| Total Current Assets | $35.8M |
| PP&E (Net) | $7.7M |
| Goodwill | $3.8M |
| Intangible Assets | $6.2M |
| Other Non-current | $530.0K |
| Total Non-current Assets | $18.2M |
| Total Assets | $54.0M |
Analysis
Selected assets total $54.0M for Latest. The largest visible component is Cash & Equivalents at $14.6M, about 27.1% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.
Balance Sheet
Annual data · 0 periods
| Metric |
|---|
| Cash & Equivalents |
| Short-term Investments |
| Net Receivables |
| Inventory |
| Other Current Assets |
| Total Current Assets |
| Property, Plant & Equipment (Net) |
| Goodwill |
| Intangible Assets |
| Long-term Investments |
| Tax Assets |
| Other Non-current Assets |
| Total Non-current Assets |
| Total Assets |
| Account Payables |
| Short-term Debt |
| Tax Payables |
| Deferred Revenue |
| Other Current Liabilities |
| Total Current Liabilities |
| Long-term Debt |
| Deferred Tax Liabilities |
| Deferred Revenue (Non-current) |
| Other Non-current Liabilities |
| Total Non-current Liabilities |
| Total Liabilities |
| Common Stock |
| Retained Earnings |
| Accumulated OCI |
| Other Stockholders Equity |
| Minority Interest |
| Total Equity |
| Total Debt |
| Net Debt |
Competitors
Peer companies in the same sector
NeoGenomics, Inc.
NASDAQ:NEO
$290.37M
OraSure Technologies, Inc.
NASDAQ:OSUR
$287.79M
Sagimet Biosciences Inc.
NASDAQ:SGMT
$211.13M
Arcturus Therapeutics Holdings Inc.
NASDAQ:ARCT
$198.11M
Sanara MedTech Inc.
NASDAQ:SMTI
$190.70M
Humacyte, Inc.
NASDAQ:HUMA
$177.24M
Quanterix Corporation
QTRX
$146.03M
CVRx, Inc.
CVRX
$133.48M
Exagen Inc.
XGN
$112.83M
MDxHealth S.A.
MDXH
$27.85M
SEC Filings
Recent regulatory filings
No filings found.
How much cash does STXS have?
Stereotaxis, Inc. (STXS) reported $13.42M in cash and equivalents in fiscal 2025.
How much debt does STXS carry?
Stereotaxis, Inc. (STXS) reported $5.44M of total debt, with net debt of -$7,985,000.00.
Explore More
Continue the stock analysis
Jump to another research area for this company.